Table 2.
Characteristics of cases in propensity score matched cohort (n=37 158) of patients who did or did not receive at least one intermediate acting non-depolarizing neuromuscular blocking agent. Values are frequencies (percentages) unless stated otherwise
| Subgroups | Neuromuscular blocking agents | |
|---|---|---|
| Received (n=18 579) | Not received (n=18 579) | |
| Age (years): | ||
| 1-9 | 795 (4.3) | 733 (4.0) |
| 10-19 | 958 (5.2) | 938 (5.1) |
| 20-29 | 1446 (7.8) | 1419 (7.6) |
| 30-39 | 1951 (10.5) | 1971 (10.6) |
| 40-49 | 3193 (17.2) | 3220 (17.3) |
| 50-59 | 3707 (20.0) | 3738 (20.1) |
| 60-69 | 3252 (17.5) | 3268 (17.6) |
| 70-79 | 1840 (9.9) | 1831 (9.9) |
| ≥80 | 750 (4.0) | 759 (4.1) |
| Missing | 687 (3.7) | 702 (3.8) |
| Mean (SD) | 48.9 (20.0) | 49.1 (19.8) |
| Female | 9638 (51.9) | 9535 (51.3) |
| Male | 8941 (48.1) | 9044 (48.7) |
| Body weight (kg): | ||
| <60 | 3265 (17.6) | 3150 (17.0) |
| 60-69.9 | 3225 (17.4) | 3217 (17.3) |
| 70-80.9 | 3416 (18.4) | 3441 (18.5) |
| 81-94.9 | 3259 (17.5) | 3386 (18.2) |
| ≥95 | 3579 (19.3) | 3526 (19.0) |
| Missing | 1835 (9.9) | 1859 (10.0) |
| Mean (SD) | 77.5 (25.8) | 77.1 (25.8) |
| ASA score: | ||
| 1 | 3230 (17.4) | 3182 (17.1) |
| 2 | 10 892 (58.6) | 10 905 (58.7) |
| 3 | 3965 (21.3) | 3989 (21.5) |
| ≥4 | 202 (1.1) | 196 (1.1) |
| Missing | 290 (1.6) | 307 (1.7) |
| Mean (SD) | 2.1 (0.7) | 2.1 (0.7) |
| Charlson comorbidity index: | ||
| 0 | 10 069 (54.2) | 10 083 (54.3) |
| 1 | 2945 (15.9) | 2891 (15.6) |
| 2 | 1566 (8.4) | 1555 (8.4) |
| 3 | 2212 (11.9) | 2248 (12.1) |
| 4 | 940 (5.1) | 922 (5.0) |
| 5 | 312 (1.7) | 329 (1.8) |
| ≥6 | 535 (2.9) | 551 (3.0) |
| Mean (SD) | 1.3 (2.2) | 1.3 (2.2) |
| Surgical specialty: | ||
| Burn | 217 (1.2) | 235 (1.3) |
| Cardiac surgery | 26 (0.1) | 18 (0.1) |
| General surgery | 2783 (15.0) | 2624 (14.1) |
| Gynecology | 1486 (8.0) | 1581 (8.5) |
| Neurosurgery | 1267 (6.8) | 1200 (6.5) |
| Oral/maxillofacial surgery | 356 (1.9) | 347 (1.9) |
| Orthopedic surgery | 4397 (23.7) | 4546 (24.5) |
| Pediatric surgery | 974 (5.2) | 921 (5.0) |
| Plastic surgery | 823 (4.4) | 876 (4.7) |
| Surgical oncology | 1317 (7.1) | 1198 (6.5) |
| Thoracic surgery | 1320 (7.1) | 1391 (7.5) |
| Transplant surgery | 328 (1.8) | 353 (1.9) |
| Trauma surgery | 641 (3.5) | 624 (3.4) |
| Urology | 1924 (10.4) | 1967 (10.6) |
| Vascular surgery | 479 (2.6) | 470 (2.5) |
| Other | 45 (0.2) | 26 (0.1) |
| Missing | 196 (1.1) | 202 (1.1) |
| Duration of surgery (min): | ||
| <120 | 12 609 (67.9) | 12 836 (69.1) |
| ≥120 | 5845 (31.5) | 5652 (30.4) |
| Missing | 125 (0.7) | 91 (0.5) |
| Mean (SD) | 100.1 (95.4) | 102.6 (101.5) |
| Emergency case | 635 (3.4) | 672 (3.6) |
| Missing | 290 (1.6) | 307 (1.7) |
| Volatile anesthetics | 17 134 (92.2) | 17 103 (92.1) |
| Nitrous oxide | 15 803 (85.1) | 15 729 (84.7) |
| Strategies to avoid residual neuromuscular blockade: | ||
| Neostigmine | 11 737 (63.2) | NA |
| Neuromuscular transmission monitoring | 9081 (48.9) | NA |
| Neostigmine plus neuromuscular transmission monitoring | 6732 (36.2) | NA |
ASA=American Society of Anesthesiologists; NA=not applicable. Percentages may not add up to 100% because of rounding.